On Aug. 26, 2020, VBI Vaccines announced data from three preclinical mouse studies conducted to enable selection of optimized clinical candidates for the companyﾒs coronavirus program, VBI-2900. As a result of these studies, VBI has selected two vaccine candidates, with the potential to be one-dose vaccines, to take into an adaptive Phase 1/2 human clinical study, expected to begin around year-end 2020, subject to regulatory approval.